| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.7 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.7 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |